Vertex Pharmaceuticals Investor Relations Material
Latest events
M&A Announcement
Vertex Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Vertex Pharmaceuticals Inc
Access all reports
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Its products include KALYDECO (ivacaftor), ORKAMBI (lumacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), VX-445, and VX-659, as well as other product candidates at various stages of research, development, and commercialization. The company has collaboration agreements with CRISPR Therapeutics AG; Moderna, Inc.; CRISPR Therapeutics AG; Editas Medicine, Inc.; Frontline BioVentures; Merck & Co., Inc.; Cystic Fibrosis Foundation Therapeutics, Incorporated; Bristol-Myers Squibb Company; Altimmune, Inc.; and Tesaro, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Key slides for Vertex Pharmaceuticals Inc
Q3 2023
Vertex Pharmaceuticals Inc
Q4 2023
Vertex Pharmaceuticals Inc
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States